Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 3Recruiting 2No longer available 1

Sponsor Class

OTHER 10INDUSTRY 6NETWORK 3NIH 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 2Gastrointestinal 1

Conditions

Leukemia 4Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Recurrence 1Colorectal Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × revumenib × Clear all
NCT07211958 2026-05-20

REVEAL-ND NPM1

Syndax Pharmaceuticals

Phase 3 Recruiting
468 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05731947 2026-01-29

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Syndax Pharmaceuticals

Phase 1/2 Completed
42 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

NCT05406817 2025-01-10

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Syndax Pharmaceuticals

Phase 1 Completed
9 enrolled
Other hematologic neoplasm

Leukemia

NCT05326516 2024-08-13

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡